CTLA4 and pneumonitis: ICI pneumonitis is a rare condition (estimated incidence of 4% for anti-PD-1, 2% for anti-PD-L1, and <1% for anti-CTLA-4, reaching up to 10% with combination immunotherapy), but is potentially fatal, resulting from inflammation of the lung parenchyma secondary to the administration of these drugs [24].